dc.contributor.author | Chen, Jiayu | es_ES |
dc.contributor.author | Xu-Monette, Zijun Y. | es_ES |
dc.contributor.author | Deng, Lijuan | es_ES |
dc.contributor.author | Shen, Qi | es_ES |
dc.contributor.author | Manyam, Ganiraju C. | es_ES |
dc.contributor.author | Martínez-López, Azahara | es_ES |
dc.contributor.author | Zhang, Li | es_ES |
dc.contributor.author | Montes Moreno, Santiago | es_ES |
dc.contributor.author | Carlo Visco, Carlo | es_ES |
dc.contributor.author | Tzankov, Alexandar | es_ES |
dc.contributor.author | Yin, Lihui | es_ES |
dc.contributor.author | Dybkaer, Karen | es_ES |
dc.contributor.author | Chiu, April | es_ES |
dc.contributor.author | Orazi, Attilio | es_ES |
dc.contributor.author | Zu, Youli | es_ES |
dc.contributor.author | Bhagat, Govind | es_ES |
dc.contributor.author | Richards, Kristy L. | es_ES |
dc.contributor.author | Hsi, Eric D. | es_ES |
dc.contributor.author | Piris Pinilla, Miguel Ángel | es_ES |
dc.contributor.author | Choi, William W.L. | es_ES |
dc.contributor.other | Universidad de Cantabria | es_ES |
dc.date.accessioned | 2017-04-03T09:03:27Z | |
dc.date.available | 2017-04-03T09:03:27Z | |
dc.date.issued | 2015-03-20 | es_ES |
dc.identifier.issn | 1949-2553 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10902/10773 | |
dc.description.abstract | Abnormal expression of the chemokine receptor CXCR4 plays an essential role in tumor cell dissemination and disease progression.However, the significance of CXCR4 overexpressionin de nava diffuse large B cell lymphoma (DLBCL) is unknown. n 743 patfents with de novo diffuse large B celllymphoma (DLBCL) who recelved standard Rltuxlmab-CHOPimmunochemotherapy,we assessed the expression of CXCR4 and dlSHCted its prognostic signiftcenceIn various DLBCL subsets. Our results showed that CXCR4+ patients was associated wlth mala,bulky tumor,high Ki-67indax,actlvatfld B-cell-like (ABC) subtype,and Myc,Bcl-2 or p53 overexpression.Moreover, CXCR4+ was an independent factor predictlng poorer progression-free survival n germinal center B-cell-like (GCB)-DLBCL,but not In ABC-DLBCL; and in patients wlth an IPI of S2,but not in those with an IPl>2. The lack of prognostic signiflcance of CXCR4 In ABC-DLBCL was likely due to the actlvatlon of p53 tumor suppressor attenuatlng CXCR4 signaling. Furthermore,concurrent CXCR4+ and BCL2 translocatlon showed dlsmal outcomes resembling but lndependent of MYC/ BCL2 double-hlt DLBCL.Gene expression profiling suggested that alteratlons in the tumor microenvlronment and lmmune responses,increased tumor prollferation and survival,and the dlsseminatlon of CXCR4+ tumor cells to distant organs or tissues were underlying molecular mechanisms responsible for the CXCR4+ associated poor prognosis. | es_ES |
dc.format.extent | 18 p. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Impact Journals | es_ES |
dc.rights | Atribución 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Oncotarget, 20 March 2015, Vol. 6, Nº 8, pages 5597-5614 | es_ES |
dc.title | Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | openAccess | es_ES |
dc.identifier.DOI | 10.18632/oncotarget.3343 | es_ES |
dc.type.version | publishedVersion | es_ES |